Clinical trial
Efficacy and Safety of Subcutaneous Immunotherapy in Birch Pollen Allergic…
NCT00410930 · Stallergenes Greer, Industry · Terminated
Key facts
| NCT number | NCT00410930 |
|---|---|
| Title | Efficacy and Safety of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients |
| Official title | Double-Blind Placebo-Controlled Study of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients |
| Lead sponsor | Stallergenes Greer, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Allergy |
| Intervention type | Biological |
| Interventions | Subcutaneous immunotherapy - Recombinant birch pollen |
| Enrollment | 160 |
| Start date | Nov 1, 2002 |
| Completion | Nov 1, 2005 |
| First posted | Dec 13, 2006 |
| Last update posted | Dec 19, 2006 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: